RxDoctor Payments DataLook up a doctor →

Jennifer Bednarz, APRN

Nurse Practitioner · Des Plaines, ILNPI 1306498571

Payments from drug & device makers

$11,016in general payments, 2019–2025

Across 471 payments — averaging $23.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • AstraZeneca$710
  • Merck$696
  • Lilly USA, LLC$571
  • Takeda Pharmaceuticals U.S.A., Inc.$470
  • Johnson & Johnson$448
  • plus $7K from 54 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis57$1,116
AstraZeneca(2 entities)36$710
Merck34$696
Lilly USA, LLC13$571
Takeda Pharmaceuticals U.S.A., Inc.16$470
Johnson & Johnson18$448
Pharmacyclics LLC, An Abbvie Company16$437
Eisai Inc.19$412
Regeneron Healthcare Solutions, Inc.22$405
Astellas Pharma US Inc13$391
AbbVie18$341
Seagen Inc.12$307
Pfizer13$268
Incyte Corporation7$220
Amgen12$211
E.r. Squibb & Sons, L.L.C.11$207
Genentech USA, Inc.10$205
Bristol Myers Squibb7$198
ADC Therapeutics America, Inc.5$191
EMD Serono, Inc.10$180
Sanofi9$178
Daiichi Sankyo Inc.8$173
Blueprint Medicines Corporation5$137
Pharmacosmos Therapeutics Inc.6$131
Sobi, Inc2$122
Jazz Pharmaceuticals Inc.4$118
Ipsen Biopharmaceuticals, Inc5$115
Bayer6$111
GSK4$109
Scpharmaceuticals Inc.1$108
Tersera Therapeutics LLC3$97
Beigene USA, Inc.5$96
Servier Pharmaceuticals LLC4$88
Beone Medicines USA, Inc.1$85
Genmab U.S., Inc.3$80
Sanofi-aventis U.S. LLC1$78
Boehringer Ingelheim3$77
Recordati_rare_diseases_inc.3$71
Deciphera Pharmaceuticals Inc.3$63
Amneal Pharmaceuticals LLC2$57
Legend Biotech USA Inc.2$46
G1 Therapeutics, Inc.2$44
Blue Earth Diagnostics2$43
CTI Biopharma Corp.2$42
Agios Pharmaceuticals, Inc.2$41
Coherus Oncology, Inc.2$40
AVEO Pharmaceuticals, Inc.2$40
Array Biopharma Inc2$37
Stemline Therapeutics Inc.2$36
Iovance Biotherapeutics, Inc.1$32
GE HealthCare1$31
Springworks Therapeutics, Inc.1$30
Sumitomo Pharma America, Inc.1$29
Pharmaessentia USA Corporation1$29
Tempus AI, Inc1$28
Immunocore Limited1$25
Novo Nordisk1$25
Spectrum Pharmaceuticals Inc.1$25
Adaptive Biotechnologies Corporation1$24
Organon1$24

How this compares

$11,016 in reported general payments places this provider in the 95th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois →

Medicare billing

Part B allowed, 2024
$114,353
Medicare patients
230
Services billed
2,632

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nurse practitioner in Des Plaines

See the full list for Illinois →

Where these figures come from

Is this you, or does something look wrong? →